A carregar...
SGLT2 Inhibitors as Adjunctive Therapy for Type 1 Diabetes: Balancing Benefits versus Risks
Sodium glucose cotransporter-2 (SGLT-2) inhibitors are approved to treat type 2 diabetes. These drugs provide multiple benefits – including glucose-lowering, weight loss, blood pressure lowering, and decreasing the risk of major adverse cardiovascular events. To address the high unmet medical need a...
Na minha lista:
| Publicado no: | Lancet Diabetes Endocrinol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6872914/ https://ncbi.nlm.nih.gov/pubmed/31585721 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2213-8587(19)30154-8 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|